[A26-06] Mirvetuximab soravtansine (ovarian cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 04.05.2026
Project no.:
A26-06
Commission:
Commission awarded on 28.01.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with folate receptor-alpha positive, platinum-resistant high grade serous epithelial ovarian cancer who have received 1 to 3 prior systemic treatment regimens
- Patients for whom monotherapy with paclitaxel, PLD or topotecan is a suitable therapy: indication of a major added benefit
- Patients for whom combination therapy with bevacizumab is a suitable therapy: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-06
| Project no. | Title | Status |
|---|---|---|
| G24-36 | Mirvetuximab soravtansin (ovarian cancer) – Assessment in accordance with §35a (1) Sentence 11 Social Code Book (SGB) V | Commission completed |